Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Psychopharmacology

• Publication date

  2008-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00213-007-1014-6PMID 18060387
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anxiogenic-Like Behavioral Phenotype of Mice Deficient in Phosphodiesterase 4B (PDE4B)

  2008cited by this paper
• Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.

  2007cited by this paper
• Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme.

  2007cited by this paper
• The PDE4B gene confers sex-specific protection against schizophrenia

  2007influential reference
• Behavioral phenotypes of Disc1 missense mutations in mice.

  2007cited by this paper
• Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme

  2007cited by this paper
• Regulation of phosphodiesterase-4 (PDE4) expression in mouse brain by repeated antidepressant treatment: comparison with rolipram.

  2006cited by this paper
• Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function.

  2006cited by this paper
• Effect of Morris water maze diameter on visual-spatial learning in different mouse strains.

  2006cited by this paper
• Selective Phosphodiesterase (PDE)-4 Inhibitors

  2006cited by this paper
• Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use

  2006cited by this paper
• Improving memory: a role for phosphodiesterases.

  2006cited by this paper
• Forebrain D1 function and sensorimotor gating in rats: effects of D1 blockade, frontal lesions and dopamine denervation.

  2006cited by this paper
• Phosphodiesterase-4 as a potential drug target

  2005cited by this paper
• Generation of PDE4 knockout mice by gene targeting.

  2005cited by this paper
• Brain serotonin depletion by lesions of the median raphe nucleus enhances the psychotomimetic action of phencyclidine, but not dizocilpine (MK-801), in rats.

  2005cited by this paper
• PCP: from pharmacology to modelling schizophrenia.

  2005cited by this paper
• Phosphodiesterase inhibitors for cognitive enhancement.

  2005cited by this paper
• DISC1 and PDE4B Are Interacting Genetic Factors in Schizophrenia That Regulate cAMP Signaling

  2005influential reference
• Rolipram attenuates MK-801-induced deficits in latent inhibition.

  2005cited by this paper
• Species differences in behavioural effects of rolipram and other adenosine cyclic 3h, 5h-monophosphate phosphodiesterase inhibitors

  2005cited by this paper
• Keynote review: phosphodiesterase-4 as a therapeutic target.

  2005cited by this paper
• Prepulse inhibition of the acoustic startle response of rats is reduced by 6-hydroxydopamine lesions of the medial prefrontal cortex

  2005cited by this paper
• Impaired passive avoidance learning in mice lacking central neuronal nicotinic acetylcholine receptors.

  2004cited by this paper
• Interaction of metoprolol with lorazepam and bromazepam

  2004cited by this paper
• In-patient major depression: is rolipram as effective as amitriptyline?

  2004cited by this paper
• Schizophrenia: from dopamine to glutamate and back.

  2004cited by this paper
• The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors

  2004cited by this paper
• Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications.

  2004cited by this paper
• Dopaminergic stimulation disrupts sensorimotor gating in the rat

  2004cited by this paper
• Functional dissociation between serotonergic pathways in dorsal and ventral hippocampus in psychotomimetic drug‐induced locomotor hyperactivity and prepulse inhibition in rats

  2004cited by this paper
• Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4).

  2004cited by this paper
• The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges.

  2004cited by this paper
• Cyclic AMP-specific PDE4 Phosphodiesterases as Critical Components of Cyclic AMP Signaling*

  2003cited by this paper
• Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis.

  2002cited by this paper
• The role of hippocampal dopamine receptors in prepulse inhibition

  2002cited by this paper
• A half-century of neurotransmitter research: impact on neurology and psychiatry

  2002cited by this paper
• Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses

  2002cited by this paper
• Depletion of 5-HT Disrupts Prepulse Inhibition in Rats: Dependence on the Magnitude of Depletion, and Reversal by a 5-HT Precursor

  2002cited by this paper
• Antidepressant-like Profile and Reduced Sensitivity to Rolipram in Mice Deficient in the PDE4D Phosphodiesterase Enzyme

  2002cited by this paper
• NOBEL LECTURE: A Half-Century of Neurotransmitter Research: Impact on Neurology and Psychiatry

  2001cited by this paper
• Performance of heterozygous brain-derived neurotrophic factor knockout mice on behavioral analogues of anxiety, nociception, and depression.

  2001cited by this paper
• Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review

  2001cited by this paper
• Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain.

  2000cited by this paper
• Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells.

  2000cited by this paper
• Effects of rolipram, a selective inhibitor of phosphodiesterase 4, on hyperlocomotion induced by several abused drugs in mice.

  2000influential reference
• Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice.

  1999influential reference
• Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect

  1999cited by this paper
• Chronic Antidepressant Administration Increases the Expression of cAMP-Specific Phosphodiesterase 4A and 4B Isoforms

  1999cited by this paper
• Localizing haloperidol effects on sensorimotor gating in a predictive model of antipsychotic potency.

  1998cited by this paper
• Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: identification and differential expression of immunologically distinct forms in the rat brain.

  1998cited by this paper
• Noradrenergic Activity Differentially Regulates the Expression of Rolipram‐Sensitive, High‐Affinity Cyclic AMP Phosphodiesterase (PDE4) in Rat Brain

  1997cited by this paper
• Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.

  1997cited by this paper
• Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.

  1996cited by this paper
• 5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats

  1996cited by this paper
• Prepulse inhibition and latent inhibition: the role of dopamine in the medial prefrontal cortex.

  1996cited by this paper
• 5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats

  1996cited by this paper
• Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family.

  1995cited by this paper
• Identification of two splice variant forms of type-IVB cyclic AMP phosphodiesterase, DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in brain: selective localization in membrane and cytosolic compartments and differential expression in various brain regions.

  1994cited by this paper
• Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats.

  1994cited by this paper
• Deficient Sensorimotor Gating After 6‐Hydroxydopamine Lesion of the Rat medial Prefrontal Cortex is Reversed by Haloperidol

  1994cited by this paper
• Antinociceptive effect of brain-derived neurotrophic factor and neurotrophin-3.

  1994cited by this paper
• Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate.

  1993cited by this paper
• A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder.

  1992cited by this paper
• Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle.

  1991cited by this paper
• Rolipram in Major Depressive Disorder: Results of a Double-Blind Comparative Study with Imipramine

  1989cited by this paper
• Antidepressant effects of rolipram in a genetic animal model of depression: cholinergic supersensitivity and weight gain.

  1989cited by this paper
• The current status of the dopamine hypothesis of schizophrenia.

  1988cited by this paper
• The effect of a selective phosphodiesterase inhibitor, rolipram, on muricide in olfactory bulbectomized rats.

  1988cited by this paper
• Rolipram versus imipramine in inpatients with major, "minor" or atypical depressive disorder: a double-blind double-dummy study aimed at testing a novel therapeutic approach.

  1988cited by this paper
• Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics.

  1986cited by this paper
• Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors.

  1986cited by this paper
• Brain cAMP response to phosphodiesterase inhibitors in rats killed by microwave irradiation or decapitation.

  1984cited by this paper
• Developments of a water-maze procedure for studying spatial learning in the rat.

  1984cited by this paper
• Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors.

  1983influential reference
• Behavioral despair in mice: a primary screening test for antidepressants.

  1977cited by this paper
• Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse

  1968cited by this paper

• The cAMP-phosphodiesterase PDE4B2 controls peroxisome proliferator-activated receptor γ (PPARγ) expression and the initiation of adipogenesis in 3T3-L1 cells.

  2025cites this paper
• Phosphodiesterase 4 Inhibition in Neuropsychiatric Disorders Associated with Alzheimer’s Disease

  2025cites this paper
• Cyclic nucleotide phosphodiesterases as drug targets.

  2025cites this paper
• Potential of phosphodiesterase 4B inhibitors in the treatment of interstitial lung disease associated with autoimmune diseases.

  2024cites this paper
• Reply to Charles V. Vorhees: Aspartame and anxiety-like behavior

  2023cites this paper
• Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis

  2023cites this paper
• Phosphodiesterase inhibitors in psychiatric disorders

  2023cites this paper
• Forebrain-specific conditional calcineurin deficiency induces dentate gyrus immaturity and hyper-dopaminergic signaling in mice

  2022cites this paper
• PDE4B Proposed as a High Myopia Susceptibility Gene in Chinese Population

  2022cites this paper
• Forebrain-speci�c conditional calcineurin de�ciency induces dentate gyrus immaturity and hyperdopaminergic signaling in mice

  2022cites this paper
• Targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement.

  2022cites this paper
• Neuronal lack of PDE7a disrupted working memory, spatial learning, and memory but facilitated cued fear memory in mice.

  2022cites this paper
• Selective Inhibition of PDE4B Reduces Binge Drinking in Two C57BL/6 Substrains

  2021cites this paper
• Phosphodiesterase-5 inhibitors: Shedding new light on the darkness of depression?

  2020cites this paper
• Dominant-Negative Attenuation of cAMP-Selective Phosphodiesterase PDE4D Action Affects Learning and Behavior

  2020cites this paper
• Genetic manipulation of cyclic nucleotide signaling during hippocampal neuroplasticity and memory formation.

  2020cites this paper
• Novel, potent, selective, and brain penetrant phosphodiesterase 10A inhibitors.

  2019cites this paper
• Early Emotional Symptoms Predicting Carotid Atherosclerosis in Youth: Results From a Birth Cohort in Latin America

  2019cites this paper
• Novel, potent, selective and brain penetrant phosphodiesterase 10A inhibitors

  2019cites this paper
• Propofol Alters Long Non-Coding RNA Profiles in the Neonatal Mouse Hippocampus: Implication of Novel Mechanisms in Anesthetic-Induced Developmental Neurotoxicity

  2018cites this paper
• A negative allosteric modulator of PDE4D enhances learning after traumatic brain injury

  2018cites this paper
• Variants in regulatory elements of PDE4D associate with major mental illness in the Finnish population

  2018cites this paper
• Expression and significance of phosphodiesterase 4B gene in peripheral blood of patients with oral lichen planus

  2018cites this paper
• Genetics of suicide attempts in individuals with and without mental disorders: a population-based genome-wide association study

  2018cites this paper
• Discovery of N-Alkyl Catecholamides as Selective Phosphodiesterase-4 Inhibitors with Anti-neuroinflammation Potential Exhibiting Antidepressant-like Effects at Non-emetic Doses.

  2017cites this paper
• Phosphodiesterase-4B as a Therapeutic Target for Cognitive Impairment and Obesity-Related Metabolic Diseases.

  2017cites this paper
• Role of Phosphodiesterases in Huntington's Disease.

  2017cites this paper
• Transcriptome sequencing study implicates immune-related genes differentially expressed in schizophrenia: new data and a meta-analysis

  2017cites this paper
• Saffron (Crocus sativus L.) Tea Intake Prevents Learning/Memory Defects and Neurobiochemical Alterations Induced by Aflatoxin B1 Exposure in Adult Mice

  2017cites this paper
• Altered phosphorylation, electrophysiology, and behavior on attenuation of PDE4B action in hippocampus

  2017cites this paper
• Phosphodiesterase-1b (Pde1b) knockout mice are resistant to forced swim and tail suspension induced immobility and show upregulation of Pde10a

  2017cites this paper
• Regulation of Striatal Signaling by Protein Phosphatases

  2017cites this paper
• Regulation of Striatal Neuron Activity by Cyclic Nucleotide Signaling and Phosphodiesterase Inhibition: Implications for the Treatment of Parkinson's Disease.

  2017cites this paper
• The impact of Disrupted-in-Schizophrenia 1 (DISC1) on the dopaminergic system: a systematic review

  2017cites this paper
• The PDE4 cAMP-Specific Phosphodiesterases: Targets for Drugs with Antidepressant and Memory-Enhancing Action.

  2017cites this paper
• A comparison of the sexually dimorphic dexamethasone transcriptome in mouse cerebral cortical and hypothalamic embryonic neural stem cells.

  2017cites this paper
• Phosphodiesterases: CNS Functions and Diseases

  2017influential citation
• PDE Inhibitors for the Treatment of Schizophrenia.

  2017cites this paper
• Copy-number variations in DISC 1 and DISC 1-interacting partners in major mental illness

  2016cites this paper
• Compartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory

  2016cites this paper
• The effect of resveratrol on beta amyloid-induced memory impairment involves inhibition of phosphodiesterase-4 related signaling

  2016cites this paper
• Enhancing cAMP Levels as Strategy for the Treatment of Neuropsychiatric Disorders.

  2016cites this paper
• Phosphodiesterase 4 inhibitors and drugs of abuse: current knowledge and therapeutic opportunities

  2016cites this paper
• Chronic Cognitive Dysfunction after Traumatic Brain Injury Is Improved with a Phosphodiesterase 4B Inhibitor

  2016cites this paper
• The Role of Protein Kinase A in Anxiety Behaviors

  2016cites this paper
• MEK Inhibitors Reverse cAMP-Mediated Anxiety in Zebrafish

  2015cites this paper
• From neural to genetic substrates of panic disorder: Insights from human and mouse studies.

  2015cites this paper
• Schizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models

  2015cites this paper
• PDE and cognitive processing: beyond the memory domain.

  2015cites this paper
• Specific Inhibition of Phosphodiesterase-4B Results in Anxiolysis and Facilitates Memory Acquisition

  2015cites this paper
• Genome-wide association study of patient and clinician rated global impression severity during antipsychotic treatment

  2014cites this paper
• Select 3',5'-cyclic nucleotide phosphodiesterases exhibit altered expression in the aged rodent brain.

  2014cites this paper
• Phosphodiesterase: an interface connecting cognitive deficits to neuropsychiatric and neurodegenerative diseases.

  2014cites this paper
• Selective Phosphodiesterase 4B Inhibitors: A Review

  2014cites this paper
• Emerging Role for PDE4 in Neuropsychiatric Disorders: Translating Advances from Genetic Studies Into Relevant Therapeutic Strategies

  2014cites this paper
• Phosphodiesterases and Cyclic Nucleotide Signaling In The CNS

  2014cites this paper
• Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.

  2014cites this paper
• The Role of Phosphodiesterases in Dopamine Systems governing Motivated Behavior

  2014cites this paper
• Disrupted-In-Schizophrenia-1 (DISC1) interactome and mental disorders: impact of mouse models.

  2014cites this paper
• Functional characterisation of phosphodiesterase 4D7 in prostate cancer

  2014cites this paper
• Phosphodiesterases as therapeutic targets for Huntington's disease.

  2014cites this paper
• PDE4 as a target for cognition enhancement

  2013cites this paper
• Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment

  2013cites this paper
• Can PDE inhibition improve cognition? : Translational insights

  2013cites this paper
• Review: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition.

  2013cites this paper
• Chlorbipram: a novel PDE4 inhibitor with improved safety as a potential antidepressant and cognitive enhancer.

  2013cites this paper
• Leading compounds for the validation of animal models of psychopathology

  2013cites this paper
• Genomics of pain in osteoarthritis

  2013cites this paper
• INVESTIGATION OF SCHIZOPHRENIA RELATED GENES AND PATHWAYS THROUGH GENOME WIDE ASSOCIATION STUDIES

  2013cites this paper
• The role of PKC signaling in CRF-induced modulation of startle

  2013cites this paper
• Integrating neurotransmission in striatal medium spiny neurons.

  2012cites this paper
• Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction

  2012cites this paper
• Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap

  2012cites this paper
• Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.

  2012cites this paper
• Avoiding mouse traps in schizophrenia genetics: lessons and promises from current and emerging mouse models.

  2012cites this paper
• Phosphodiesterases as therapeutic targets for Alzheimer's disease.

  2012cites this paper
• Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex

  2011cites this paper
• Taking a bird's eye view on a mouse model review: a comparison of findings from mouse models targeting DISC1 or DISC1-interacting proteins

  2011influential citation
• Phosphodiesterase-4D Knock-Out and RNA Interference-Mediated Knock-Down Enhance Memory and Increase Hippocampal Neurogenesis via Increased cAMP Signaling

  2011cites this paper
• Cognitive deficits, behavioral changes and gene expression profiling in a mouse model of repeated mild traumatic brain injury

  2011cites this paper
• Role of Neuropeptide Y in Depression: Current Status

  2011cites this paper
• Enhanced long-term depression and impaired reversal learning in phosphodiesterase 4B-knockout (PDE4B-/-) mice.

  2011cites this paper
• Effects of Repeated Treatment with Phosphodiesterase-4 Inhibitors on cAMP Signaling, Hippocampal Cell Proliferation, and Behavior in the Forced-Swim Test

  2011cites this paper
• Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders.

  2011cites this paper
• Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions.

  2011cites this paper
• Molecular characterization of an interstitial deletion of 1p31.3 in a patient with obesity and psychiatric illness and a review of the literature

  2011cites this paper
• Inhibition of phosphodiesterase-4 decreases ethanol intake in mice

  2011cites this paper
• PAGES_DCNS 46_5.qxd:DCNS#45

  2010cites this paper
• Role of phosphodiesterases in dopamine signal transduction.

  2010cites this paper
• Molecules, signaling, and schizophrenia.

  2010cites this paper
• Cyclic GMP and Nitric Oxide Synthase in Aging and Alzheimer's Disease

  2010cites this paper
• DISC1 & GSK3β modulate PDE4 activity: functional integration of psychiatric associated signalling pathways

  2010cites this paper
• Modeling the Positive Symptoms of Schizophrenia in Genetically Modified Mice: Pharmacology and Methodology Aspects

  2010cites this paper
• Comprehensive genetic association analysis of genes from the Reelin and DISC1 networks in schizophrenia and neurocognitive endophenotypes

  2010cites this paper
• Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission.

  2010cites this paper
• Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

  2010cites this paper
• Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes

  2010cites this paper
• Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues.

  2010cites this paper
• Phosphodiesterases in the central nervous system.

  2009cites this paper
• Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs.

  2009cites this paper